Live Attenuated Coronavirus Vaccines

The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.

Website
U.S. Patent 7,452,542: Live attenuated coronavirus vaccines

Inventors: 
Mark Denison
Licensing manager: 
Mike Villalobos

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter